New research suggests that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds much more quickly than those who stop traditional lifestyle plans.
Findings released in a major medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users using such medications should be informed of the potential of rapid weight regain when the treatment ends," stated expert Dr. Susan Jebb.
This pace of regain suggests a reversion to pre-treatment mass within about one and a half years.
Analyzing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
Scientists note that people who lose weight through lifestyle changes alone typically experience a less rapid weight regain—around 0.1 kg a month—once they finish.
Understanding the Quick Regain
Doctors suggest the mechanism of the jabs explains the accelerated weight return.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
Health authorities recommend the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, due to the likelihood of weight regain, the therapy should be considered life-long.
This opinion is reinforced by drug manufacturers, who state that the results "highlight the long-term character of obesity," comparing it to managing diseases like diabetes.
User Experiences
Individuals who have stopped the jabs report a intense resurgence of appetite.
"I experienced a switch that goes on and you become ravenous," described an individual.
This difficulty is worsened if patients have not developed sustainable dietary or behavioural modifications during therapy.
Widespread Interest
Recent estimates show that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone fix and long-term success relies on combined lifestyle support.
